

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	2	"6429311".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/05 12:38
S2	20	("5798344" "6331541" "6444686" "6492400" "6521592" "6525069" "6605623" "6780857" "6875776" "6897234" "6906066" "6919368").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/31 12:15
S3	783	quinazolinone.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:07
S4	344	hansch.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:40
S5	0	hansch.in. and qsar	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:40
S6	0	hansch.in. and structure adj activity	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:41
S7	0	hansch.in. and pharma\$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:41

## EAST Search History

S8	0	hansch-\$.in. and pharma\$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:42
S9	342	hansch-\$.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:42
S10	0	hansch-\$.in. and drug	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:42
S11	2	dihydro adj quinazolinone.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:07
S12	6	quinazolinone.ab. and prostaglandin	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:16
S13	165	quinazolinone and prostaglandin	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:16
S14	159	quinazolinone and prostaglandin not S12	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:25

## EAST Search History

S15	2	"6759410".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:25
S16	5	"3375250".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/05 12:29
S17	3	"3843654".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/05 12:29
S18	3	"3843654".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/05 16:17

&gt;&gt; FILE CAPLUS

FILE 'CAPLUS' ENTERED AT 10:29:16 ON 25 MAY 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PBI) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of ACS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2007 VOL 146 ISS 23

FILE LAST UPDATED: 24 May 2007 (20070524/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply.  
 They are available for your review at:

<http://www.cas.org/infopolicy.html>  
 'OBI' is DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

>> D QUB L11  
LJ STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation:  
 Uploading strA.str



Page 1 of 27

chain nodes :  
 11 12 15 16 17 23 24 25 26 27 28 29 30 31 32 33 34 35 42 43 44  
 58 59 66 67  
 ring nodes :  
 1 2 3 4 5 6 7 8 9 10 18 19 20 21 22 36 37 38 39 40 41 45 46  
 47 48 49 50 51 52 53 54 55 56 57  
 chain bonds :  
 7-11 8-66 9-15 16-17 17-18 23-24 24-25 25-26 25-27 26-29 29-30 30-31  
 31-32 31-33 34-35 35-36 39-42 42-43 42-44 45-58 51-67 58-59  
 ring bonds :  
 1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 18-19 18-22 19-20 20-21  
 21-22 36-37 36-41 37-38 38-39 39-40 40-41 45-46 45-50 46-47 47-48 48-49  
 49-51 51-52 52-53 52-54 53-57 54-55 55-56 56-57  
 exact/norm bonds :  
 4-7 5-10 7-8 7-11 8-9 8-66 9-10 9-15 16-17 18-19 18-22 19-20 20-21 21-  
 22 23-24 28-29 34-35 39-42 48-51 49-53 51-52 51-67 58-59  
 exact bonds :  
 17-18 24-25 25-26 25-27 29-30 30-31 31-32 31-33 35-36 42-43 42-44 45-58  
 normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 36-37 36-41 37-38 38-39 39-40 40-41 45-46 45-  
 50 46-47 47-48 48-49 49-50 52-53 52-54 53-57 54-55 55-56 56-57

G1:Ak, [\*1]

G2:[\*2], [\*3], [\*4], [\*5], [\*6]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
 11:CLASS 12:Atom 15:CLASS 16:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom 21:Atom  
 22:Atom 23:CLASS  
 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS  
 32:CLASS 33:CLASS  
 34:CLASS 35:CLASS 36:Atom 37:Atom 38:Atom 39:Atom 40:Atom 41:Atom 42:CLASS  
 43:CLASS  
 44:CLASS 45:Atom 46:Atom 47:Atom 48:Atom 49:Atom 50:Atom 51:Atom 52:Atom  
 53:Atom 54:Atom 55:Atom 56:Atom 57:Atom 58:CLASS 59:CLASS 66:CLASS 67:CLASS

Generic attributes :

12:

Saturation : Unsaturated

67:

Number of Carbon Atoms : less than 7

L5 86 SEA FILE=REGISTRY SSS FUL L3  
 L6 4 SEA FILE=CAPLUS ABB=ON PLU=ON L5  
 L7 266 SEA FILE=CAPLUS ABB=ON PLU=ON ITAI A?/AU  
 L8 1390 SEA FILE=CAPLUS ABB=ON PLU=ON MUTO S?/AU  
 L9 11982 SEA FILE=CAPLUS ABB=ON PLU=ON INOUE T?/AU  
 L10 262 SEA FILE=CAPLUS ABB=ON PLU=ON URADA Y?/AU  
 L11 1 SEA FILE=CAPLUS ABB=ON PLU=ON (L7 OR L8 OR L9 OR L10) AND L6

Page 2 of 27

&gt;&gt; D IBIB ED ABS HITSTR L11 1

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2004:308434 CAPLUS Full-text  
 DOCUMENT NUMBER: 140:339338  
 TITLE: Preparation of quinazolin-4-one derivatives as PGD2 synthetase inhibitors  
 INVENTOR(S): Itai, Akiko; Kute, Gusuumi;  
 Inoue, Tsuyoshi; Urade, Yoshihiro  
 PATENT ASSIGNEE(S): Institute of Medicinal Molecular Design, Inc., Japan  
 SOURCE: PCT Int. Appl., 96 pp.  
 CODEN: PIKXD2


DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031180	A1	20040415	WO 2003-JP12648	20031002
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KB, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RU, SC, SD, SE, SO, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KB, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BO, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IS, LU, MC, NL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CO, CI, CM, GA, GN, QQ, GM, ML, MR, NB, SN, TD, TO				
CA 2503674	A1	20040415	CA 2003-2503674	20031002
AU 2003268735	A1	20040423	AU 2003-268735	20031002
GB 2410025	A	20050720	GB 2005-7682	20031002
GB 2410025	B	20070328		
US 20062293324	A1	20061012	US 2005-529946	20051004
PRIORITY APPLN. INFO.:				
JP 2002-291114	A	20021003		
WO 2003-JP12648	W	20031002		

OTHER SOURCE(S): MARPAT 140:339338

ED Entered STN: 15 Apr 2004

GI




AB The title compds. I (wherein X = (un)substituted N=CH or NHCH2; R1-R4 = independently H, halo, (un)substituted alkyl, or OH; R = (un)substituted NH3+ or pharmaceutically acceptable salts, hydrates, or solvates thereof are

Page 3 of 27


prepared as prostaglandin D2 synthase (PGD2) inhibitors. For example, the compound II was prepared in a four-step synthesis. Compd. I showed strong inhibitory effect against human PGD2.

IT 679843-64-2  
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PVP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USB3 (Uses)  
 (drug candidate; preparation of quinazolinone derivs. as PGD2 synthetase inhibitors)  
 RN 679843-64-2 CAPLUS  
 CN 4(1H)-Quinazolinone, 2,3-dihydro-2-(hydroxymethyl)-3-[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino-, (9CI) (CA INDEX NAME)



IT 679843-65-3  
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USB3 (Uses)  
 (drug candidate; preparation of quinazolinone derivs. as PGD2 synthetase inhibitors)  
 RN 679843-65-3 CAPLUS  
 CN 4(1H)-Quinazolinone, 2,3-dihydro-2-(hydroxymethyl)-3-[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry unknown.




IT 679843-66-4 CAPLUS  
 CN 4(1H)-Quinazolinone, 2,3-dihydro-2-(hydroxymethyl)-3-[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.


i




IT 679843-30-2P 679843-34-6P 679843-35-7P  
679843-37-9P 679843-38-0P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of quinazolinone derivs. as PGD2 synthetase inhibitors)  
RN 679843-30-2 CAPLUS  
CN Acetic acid, [(3-methyl-4-[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl-1H-pyrazol-5-yl]oxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 679843-34-6 CAPLUS  
CN 1H-Pyrazole-3-propenoic acid, 5-hydroxy-4-[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl-1-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 679843-35-7 CAPLUS  
CN 1H-Pyrazole-3-propanoic acid, 5-hydroxy-4-[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 679843-37-9 CAPLUS  
CN 1H-Pyrazole-3-butanoic acid, 5-hydroxy-4-[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl-1-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 679843-38-0 CAPLUS  
CN 1H-Pyrazole-3-butanoic acid, 5-hydroxy-4-[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl-1-phenyl- (9CI) (CA INDEX NAME)




IT 371120-60-4P 384353-13-3P 384812-90-2P  
679843-29-5P 679843-31-3P 679843-32-4P  
679843-33-5P 679843-36-8P 679843-39-1P  
679843-40-4P 679843-41-5P 679843-42-6P  
679843-43-7P 679843-44-8P 679843-45-9P  
679843-46-0P 679843-47-1P 679843-48-2P  
679843-49-3P 679843-50-6P 679843-51-7P  
679843-52-9P 679843-53-9P 679843-54-0P  
679843-55-1P 679843-56-2P 679843-57-3P  
679843-58-4P 679843-59-5P 679843-60-6P  
679843-61-9P 679843-62-0P 679843-63-1P  
679843-67-5P 679843-68-6P 679843-69-7P  
679843-70-0P 679843-71-1P 679843-72-2P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
RN 371120-60-4 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[(5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl)methylene]amino-2-methyl- (9CI) (CA INDEX NAME)




RN 384353-13-3 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino-2-methyl- (9CI) (CA INDEX NAME)




RN 384812-90-2 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-29-9 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[(5-ethoxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-31-3 CAPLUS  
CN Acetic acid, [(3-methyl-4-[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl-1H-pyrazol-5-yl]oxy-, (9CI) (CA INDEX NAME)




RN 679843-32-4 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[(3-ethyl-5-hydroxy-1-phenyl-1H-pyrazol-4-yl)methylene]amino-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-33-5 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[(5-hydroxy-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methylene]amino-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-36-8 CAPLUS  
CN 1H-Pyrazole-3-propanamide, 5-hydroxy-4-[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 679843-39-1 CAPLUS  
 CN 1H-Pyrazole-3-butanamide, 5-hydroxy-4-[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl- (9CI) (CA INDEX NAME)




RN 679843-40-4 CAPLUS  
 CN 4(3H)-Quinazolinone, 3-[(5-hydroxy-1,3-dimethyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-41-5 CAPLUS  
 CN 4(3H)-Quinazolinone, 3-[(1-(2-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-42-6 CAPLUS  
 CN 4(3H)-Quinazolinone, 3-[(1-(3-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-43-7 CAPLUS

Page 9 of 27


CN 4(3H)-Quinazolinone, 3-[(1-(4-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-44-8 CAPLUS  
 CN 4(3H)-Quinazolinone, 3-[(5-hydroxy-1-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-45-9 CAPLUS  
 CN 4(3H)-Quinazolinone, 3-[(5-hydroxy-3-methyl-1-(4-nitrophenyl)-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-46-0 CAPLUS  
 CN 4(3H)-Quinazolinone, 2-ethyl-3-[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino)- (9CI) (CA INDEX NAME)




RN 679843-47-1 CAPLUS  
 CN 4(3H)-Quinazolinone, 3-[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)

Page 10 of 27


y1)methylene]amino]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 679843-48-2 CAPLUS  
 CN 4(3H)-Quinazolinone, 2-butyl-3-[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino)- (9CI) (CA INDEX NAME)




RN 679843-49-3 CAPLUS  
 CN 4(3H)-Quinazolinone, 3-[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-phenyl- (9CI) (CA INDEX NAME)




RN 679843-50-6 CAPLUS  
 CN 4(3H)-Quinazolinone, 2-(1,1-dimethylethyl)-3-[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino)- (9CI) (CA INDEX NAME)




RN 679843-51-7 CAPLUS  
 CN 4(3H)-Quinazolinone, 2-(hydroxymethyl)-3-[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino)- (9CI) (CA INDEX NAME)




RN 679843-52-8 CAPLUS  
 CN Acetic acid, [(4-[(2-(hydroxymethyl)-4-oxo-3(4H)-quinazolinyl)imino]methyl)-3-methyl-1-phenyl-1H-pyrazol-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 679843-53-9 CAPLUS  
 CN 4(3H)-Quinazolinone, 2-(hydroxymethyl)-3-[(5-hydroxy-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methylene]amino)- (9CI) (CA INDEX NAME)




RN 679843-54-0 CAPLUS  
 CN 4(3H)-Quinazolinone, 3-[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)




RN 679843-55-1 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[[{(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino}-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 679843-56-2 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[[{(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino}-2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 679843-57-3 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[[{(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino}-2-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 679843-58-4 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[[{(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino}-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 679843-59-5 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[[{(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino}-2,8-dimethyl- (9CI) (CA INDEX NAME)




RN 679843-60-8 CAPLUS  
CN 4(3H)-Quinazolinone, 6-chloro-3-[[{(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino}-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-61-9 CAPLUS  
CN 4(3H)-Quinazolinone, 7-chloro-3-[[{(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino}-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-62-0 CAPLUS  
CN 4(3H)-Quinazolinone, 6-bromo-3-[[{(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino}-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-63-1 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[[{(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino}-6,7-dimethoxy-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-69-7 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[[{[4-(1,1-dimethylethyl)phenyl]-5-hydroxy-1-phenyl-1H-pyrazol-4-yl}methylene]amino}-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-70-0 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[[{(5-hydroxy-1-phenyl-3-tricyclo[3.3.1.13.7]dec-1-yl-1H-pyrazol-4-yl)methylene]amino}-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-67-5 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[(2,2-diphenylethylidene)amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-71-1 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[[{[4-(diphenylamino)phenyl]methylene}amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-72-2 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[[{(9-ethyl-9H-carbazol-3-yl)methylene}amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-68-6 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[[{3,3-diphenyl-2-propenylidene}amino]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

>> D QUE L6  
L3 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*  
Structure attributes must be viewed using STN Express query preparation:  
Uploading strA.str




chain nodes :  
11 12 15 16 17 23 24 25 26 27 28 29 30 31 32 33 34 35 42 43 44  
58 59 66 67  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 18 19 20 21 22 36 37 38 39 40 41 45 46  
47 48 49 50 51 52 53 54 55 56 57  
chain bonds :  
7-11 8-66 9-15 16-17 17-18 23-24 24-25 25-26 25-27 28-29 29-30 30-31  
31-32 31-33 34-35 35-36 39-42 42-43 42-44 45-58 51-67 58-59  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 18-19 18-22 19-20 20-21  
21-22 36-37 36-41 37-38 38-39 39-40 40-41 45-46 45-50 46-47 47-48 48-49  
48-51 49-50  
49-53 51-52 52-53 52-54 53-57 54-55 55-56 56-57  
exact/norm bonds :  
4-7 5-10 7-8 7-11 8-9 8-66 9-10 9-15 16-17 18-19 18-22 19-20 20-21 21-  
22  
23-24 28-29 34-35 39-42 48-51 49-53 51-52 51-67 58-59  
exact bonds :  
17-18 24-25 25-26 25-27 29-30 30-31 31-32 31-33 35-36 42-43 42-44 45-58  
normalized bonds :

Page 17 of 27

Page 18 of 27

1-2 1-6 2-3 3-4 4-5 5-6 36-37 36-41 37-38 38-39 39-40 40-41 45-46 45-  
50 46-47 47-48 48-49 49-50 52-53 52-54 53-57 54-55 55-56 56-57



G1:AK, [\*1]

G2:[\*2], [\*3], [\*4], [\*5], [\*6]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 12:Atom 15:CLASS 16:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom 21:Atom  
22:Atom 23:CLASS  
24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS  
32:CLASS 33:CLASS  
34:CLASS 35:CLASS 36:Atom 37:Atom 38:Atom 39:Atom 40:Atom 41:Atom 42:CLASS  
43:CLASS  
44:CLASS 45:Atom 46:Atom 47:Atom 48:Atom 49:Atom 50:Atom 51:Atom 52:Atom  
53:Atom 54:Atom  
55:Atom 56:Atom 57:Atom 58:CLASS 59:CLASS 66:CLASS 67:CLASS

Generic attributes :

12:

Saturation : Unsaturated

67:

Number of Carbon Atoms : less than 7


AB Some fused quinazoline derive. have been synthesized via condensation of 3-formylpyrazolo[5,1-b]quinazolin-9(1H)-one with bifunctional reagents followed by ring closure reactions. The structures of the products have been established by their elemental analyses and spectral data (UV, IR, 1H NMR, mass and X-ray). The antibacterial activity of some products have been also described. I [R = 5-oxo-3-thioxo-hexahydro-1,2,4-triazin-6-yl, CH:CHCOCH<sub>2</sub>H<sub>4</sub>R1-4; R1 = OH, NO<sub>2</sub>] show a relatively better activity against some tested bacteria than gentamycin.

IT 209746-47-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation and bactericidal activity of pyrazoloquinazoline derive.)

RN 209746-47-4 CAPLUS

CN Pyrazolo[5,1-b]quinazolin-9(4H)-one, 3-[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino)methyl]- (9CI) (CA INDEX NAMES)



L5 86 SEA FILE=REGISTRY SSS FUL L3  
L6 4 SEA FILE=CAPLUS ABB=ON PLU=ON L5

>> S L6 NOT L11  
L15 3 L6 NOT L11

&gt;&gt; D IBIB ED ABS HITSTR L15 1-3

L15 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1998:346325 CAPLUS Full-text  
DOCUMENT NUMBER: 129:95463  
TITLE: Synthesis and biological activities of some new fully fused quinazoline derivatives  
AUTHOR(S): Ibrahim, S. S.; Abdel-Halim, A. M.; Gabr, Y.; El-Edfavy, S.; Abdel-Rahman, R. M.  
CORPORATE SOURCE: Department of Chemistry, Faculty of Education, Ain-Shams University, Cairo, Egypt  
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1998), 37B(1), 62-67  
CODEN: IJSDDB; ISSN: 0376-4699  
PUBLISHER: National Institute of Science Communication, CSIR  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 129:95463  
ED Entered STN: 10 Jun 1998  
GI

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1991:122242 CAPLUS Full-text  
DOCUMENT NUMBER: 114:122242


TITLE: Non-steroidal antiinflammatory agents. III: Synthesis of pyrazole derivatives of 4(3H)-quinoxalinones

AUTHOR(S): Farghaly, Ahmed M.; Chabany, Ibrahim; Khalil, Mounir A.; Bekhit, Adnan A.

CORPORATE SOURCE: Fac. Pharm., Univ. Alexandria, Alexandria, Egypt  
SOURCE: Alexandria Journal of Pharmaceutical Sciences (1990), 4(1), 52-6

CODEN: AJPSHS; ISSN: 1110-1792  
DOCUMENT TYPE: Journal  
LANGUAGE: English

OTHER SOURCE(S): CASREACT 114:122242  
ED Entered STN: 06 Apr 1991  
GI




AB Several groups of compds. were synthesized having a pyrazole or pyrazoline moiety attached to 4(3H)-quinazolinone at the 2- or 3-position either directly or through different linkages. The linkages include methanimino, ethenyl, iminomethyl, aminomethyl or methinehydrazino grouping. Thus, acanthantranil (I) was treated with aminocoumarine II to give 4(3H)-quinazolinone III. The antiinflammatory activity of representative examples of the products is reported.

IT 132088-33-6P 132088-38-1P 132088-39-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 132088-33-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene]amino-2-methyl- (9CI) (CA INDEX NAME)



RN 132088-38-1 CAPLUS


CN 4(3H)-Quinazolinone, 2-methyl-3-[[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl)methylene]amino- (9CI) (CA INDEX NAME)




RN 132088-39-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-

yl)methylene]amino-2-phenyl- (9CI) (CA INDEX NAME)



RN 132088-40-5 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene]amino-2-methyl- (9CI) (CA INDEX NAME)




L15 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1970:43550 CAPLUS Full-text  
DOCUMENT NUMBER: 72:43550  
TITLE: Triazolylbenzoic acids and acylaminoquinazolones from benzoxazinones and carboxylic acid hydrazides  
AUTHOR(S): Ried, Walter; Peters, Bert  
CORPORATE SOURCE: Org.-Chem. Inst., Univ. Frankfurt, Frankfurt/M., Fed. Rep. Ger.  
SOURCE: Justus Liebigs Annalen der Chemie (1969), 729, 124-38  
CODEN: JLACBF; ISSN: 0075-4617  
DOCUMENT TYPE: Journal  
LANGUAGE: German  
OTHER SOURCE(S): CASREACT 72:43550  
ED Entered STN: 12 May 1984  
GI For diagram(s), see printed CA Issue.  
AB 3-(R-Substituted)-5-(R<sub>1</sub>-substituted)-4-(2-carboxyphenyl)-4H-1,2,4-triazoles (I) (R = H, Me or Ph; R<sub>1</sub> = Me, CH<sub>2</sub>CN, CH<sub>2</sub>NO<sub>2</sub>, CH<sub>2</sub>OPh, CH<sub>2</sub>NHCOR<sub>1</sub> or Ph) were prepared from 2-(R-substituted)-4H-3,1-benzoxazines and H<sub>2</sub>NNHCOR<sub>1</sub> in boiling EtOH. In hot CS<sub>2</sub>, the reaction yielded 2-(R<sub>1</sub>-substituted)-3-(R<sub>1</sub>OCH<sub>2</sub>NHC=RNHC<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>-)-3-Methyl-5-cyanomethyl-4-(2-methylphenyl)-4H-1,2,4-triazole was prepared from 2-MeC<sub>6</sub>H<sub>4</sub>:MeCl and H<sub>2</sub>NNHOCH<sub>2</sub>CN. I (R = Me, R<sub>1</sub> = CH<sub>2</sub>CN) boiled in Ac<sub>2</sub>O gave 5-hydroxy-1-methyl-4-cyano-*s*-triazolo[4,3-*e*]quinoline (II).  
IT 25380-19-2P  
RL: SPN (Synthetic preparation); PREP (Preparation)

Page 21 of 27

Page 22 of 27

(preparation of)  
RN 25380-19-2 CAPLUS  
CN Pyrazolo[1,5-*c*]quinazoline-1-carboxamide, 2,3-dihydro-5-methyl-N-(2-methyl-4-oxo-3(4H)-quinazolinyl)- (8CI) (CA INDEX NAME)



> FILE MARPAT  
FILE 'MARPAT' ENTERED AT 10:30:59 ON 25 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 146 ISS 20 (20070518/BD)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES  
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 2007078267 05 APR 2007  
DE 102005047303 05 APR 2007  
EP 1768210 28 MAR 2007  
JP 2007082903 05 APR 2007  
WO 2007041089 12 APR 2007  
GB 2430365 28 MAR 2007  
FR 2891276 30 MAR 2007  
RU 2296767 10 APR 2007  
CA 2556850 24 FEB 2007

Expanded G-group definition display now available.

> D QUE L14  
L3 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*  
Structure attributes must be viewed using STN Express query preparation.  
L14 1 SEA FILE=MARPAT SSS FUL L3

> D IB1B AB QHIT 1 L14

L14 ANSWER 1 OF 1 MARPAT COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 140:339338 MARPAT Full-text  
TITLE: Preparation of quinazolin-4-one derivatives as PGG2 synthetase inhibitors  
INVENTOR(S): Itai, Akiko; Muto, Susumu; Inoue, Tsuyoshi; Urade, Yoshihiro  
PATENT ASSIGNEE(S): Institute of Medicinal Molecular Design, Inc., Japan  
SOURCE: PCT Int. Appl., 96 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031180	A1	20040415	WO 2003-JP12648	20031002
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DR, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KR, KE, KG, KR, KZ, LC, LK, LR,				

Page 23 of 27


Page 24 of 27

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,  
 PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,  
 TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RG: GH, GN, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO  
**CA 2503674 . A1 20040415 CA 2003-2503674 200311002**  
**AU 2003268735 A1 20040423 AU 2003-268735 200311002**  
**GB 2410025 A 20050720 GB 2005-529946 200311002**  
**GB 2410025 B 20070328**  
**US 2006229324 A1 20061012 US 2005-529946 200511002**  
**PRIORITY APPLN. INFO.: NO 2003-JP12008 200311002**

*instant*

**AB** The title compds. I (wherein X = (un)substituted N=CH or NHCH<sub>2</sub>; R1-R4 = independently H, halo, (un)substituted alkyl, or OH; R = (un)substituted NH<sub>2</sub>) or pharmaceutically acceptable salts, hydrates, or solvates thereof are prepared as prostaglandin D<sub>2</sub> synthase (PGD<sub>2</sub>) inhibitors. For example, the compound II was prepared in a four-step synthesis. Compds. I showed strong inhibitory effect against human PGD<sub>2</sub>.

MSTR 1



**G1** = alkyl <containing 1-6 C> (opt. substd.)  
**G5** = 36



Patent location: claim 1  
 Note: or pharmacologically acceptable salts, hydrates or solvates

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

&gt;&gt; D HIS NOFILE

(FILE 'HOME' ENTERED AT 09:45:09 ON 25 MAY 2007)

FILE 'CAPLUS' ENTERED AT 09:32:32 ON 25 MAY 2007

E SEA ABB=ON PLU=ON US2005-529946/APPS  
**L1 1 SEA ABB=ON PLU=ON US2005-529946/APPS**  
 D SCAN  
 SEL RN

FILE 'REGISTRY' ENTERED AT 09:46:06 ON 25 MAY 2007

**L2 142 SEA ABB=ON PLU=ON (100-07-2/B1 OR 100-63-0/B1 OR 101498-88-8/B1 OR 1022-46-4/B1 OR 105-36-2/B1 OR 1073-69-4/B1 OR 112351-69-6/B1 OR 118-92-3/B1 OR 120107-46-2/B1 OR 1210-39-5/B1 OR 126592-16-3/B1 OR 126592-17-4/B1 OR 13024-90-3/B1 OR 132871-77-3/B1 OR 134-20-3/B1 OR 134017-42-6/B1 OR 136304-94-4/B1 OR 13831-31-7/B1 OR 138825-96-4/B1 OR 141-97-9/B1 OR 14212-87-4/B1 OR 14580-22-4/B1 OR 14763-20-3/B1 OR 147778-06-1/B1 OR 1710-98-1/B1 OR 1711-05-3/B1 OR 17364-41-9/B1 OR 181185-07-9/B1 OR 18600-55-0/B1 OR 1898-06-2/B1 OR 1904-60-5/B1 OR 19386-06-2/B1 OR 20676-54-4/B1 OR 26759-46-6/B1 OR 27006-77-5/B1 OR 2719-08-6/B1 OR 2749-59-9/B1 OR 321-07-3/B1 OR 3257-39-4/B1 OR 3282-10-2/B1 OR 3471-32-7/B1 OR 371120-60-4/B1 OR 38163-38-1/B1 OR 384353-13-3/B1 OR 384812-90-2/B1 OR 388109-32-6/B1 OR 40420-22-2/B1 OR 4181-05-9/B1 OR 4389-45-1/B1 OR 4389-50-8/B1 OR 488100-78-3/B1 OR 4949-44-4/B1 OR 52173-03-2/B1 OR 53904-04-4/B1 OR 55390-99-3/B1 OR 57135-06-5/B1 OR 5900-58-3/B1 OR 60288-17-7/B1 OR 60288-19-9/B1 OR 60798-06-3/B1 OR 63190-57-8/B1 OR 638-29-9/B1 OR 6402-09-1/B1 OR 658703-33-4/B1 OR 66239-68-1/B1 OR 67836-50-4/B1 OR 679843-29-9/B1 OR 679843-10-2/B1 OR 679843-31-1/B1 OR 679843-32-4/B1 OR 679843-33-5/B1 OR 679843-34-6/B1 OR 679843-35-7/B1 OR 679843-36-8/B1 OR 679843-37-9/B1 OR 679843-38-0/B1 OR 679843-39-1/B1 OR 679843-40-4/B1 OR 679843-41-5/B1 OR 679843-42-6/B1 OR 679843-43-7/B1 OR 679843-44-8/B1 OR 679843-45-9/B1 OR 679843-46-0/B1 OR 679843-47-1/B1 OR 679843-48-2/B1 OR 679843-49-3/B1 OR 679843-50-6/B1 OR 679843-51-7/B1 OR 679843-52-8/B1 OR 679843-53-9/B1 OR 679843-54-0/B1 OR 679843-55-1/B1 OR 679843-56-2/B1 OR 679843-57-3/B1 OR 679843-58-4/B1 OR 679843-59-5/B1 OR 679843-60-8/B1 OR 679843-61-9/B1 OR 679843-62-0/B1 OR 679843-63-1/B1 OR 679843-64-2/B1 OR 679843-65-3/B1 OR 679843-66-4/B1**

**L3 STRUCTURE UPLOADED****L4 4 SEA SSS SAM L3****L5 86 SEA SSS FUL L3**

FILE 'CAPLUS' ENTERED AT 10:25:07 ON 25 MAY 2007

**L6 4 SEA ABB=ON PLU=ON L5**  
**L7 266 SEA ABB=ON PLU=ON ITAI A7/AU**  
**L8 1390 SEA ABB=ON PLU=ON MUTO S7/AU**  
**L9 11982 SEA ABB=ON PLU=ON INOUE T7/AU**  
**L10 262 SEA ABB=ON PLU=ON URADA Y7/AU**  
**L11 1 SEA ABB=ON PLU=ON (L7 OR L6 OR L9 OR L10) AND L6**  
**L12 1 SEA ABB=ON PLU=ON L6 AND P/DT**

FILE 'MARPAT' ENTERED AT 10:27:30 ON 25 MAY 2007

**L13 0 SEA SSS SAM L3**  
**L14 1 SEA SSS FUL L3**

FILE 'CAPLUS' ENTERED AT 10:29:16 ON 25 MAY 2007